Canaccord raised the firm’s price target on Progyny (PGNY) to $23 from $17 and keeps a Hold rating on the shares. The firm said the company followed up on preliminary results release in early January with a solid quarter to close the books on a tumultuous 2024. Canaccord was encouraged to see member activity improve in 4Q following a disappointing 3Q, with guidance contemplating member activity being flat to down.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PGNY:
- Progyny’s Strong Financial Performance and Growth Prospects Drive Buy Rating
- Progyny’s Balanced Outlook: Strong Performance Amidst Transition Challenges and Conservative Projections
- Progyny, Inc. Reports Strong 2024 Financial Results
- Closing Bell Movers: HP slips 4% as guidance disappoints; Elastic up 15%
- Progyny sees Q1 adjusted EPS 44c-47c, consensus 40c